Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-17. (Canceled):

18. (Currently amended): A compound according to claim 17 of formula (VI)

wherein,

R1 is C1-C6 alkyl optionally substituted with 1, 2 or 3 fluorine atoms, or C3-C6 cycloalkyl wherein one C-C bond within the cycloalkyl moiety is optionally substituted by an O-C bond;

R2 is C1-C4 alkyl optionally substituted with 1, 2 or 3 fluorine atoms, C1-C4 alkoxy optionally substituted with 1, 2 or 3 fluorine atoms, or phenyl optionally substituted with 1, 2 or 3 fluorine atoms; and R5 is H or F; or a pharmaceutically acceptable salt thereof.

19. (Currently amended): The A-compound according to claim 18 of the formula

or a pharmaceutically acceptable salt thereof.

20. (Currently amended): The A-compound according to claim 19 of the formula

or a pharmaceutically acceptable salt thereof.

- 21. (Previously presented): The hydrochloride salt of a compound according to claim 20.
- 22. (Currently amended): A pharmaceutical composition, comprising a compound according to claim 18-1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent, excipient or carrier.

23-34. (Cancelled)

- 35. (Previously presented): The hydrochloride salt of a compound according to claim 19.
- 36. (Previously presented): A pharmaceutical composition, comprising a compound according to claim 20, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent, excipient or carrier.
- 37. (Previously presented): The pharmaceutical composition of claim 36, where said pharmaceutically acceptable salt is a hydrochloride salt.
- 38. (Currently amended): A method for treating attention-deficit hyperactivity disorder, a cognitive disorder, conduct disorder, oppositional defiant disorder, or depression, comprising administering to a patient in need thereof an effective amount of a compound of claim 18-1, or a pharmaceutically acceptable salt thereof.

- 39. (Currently amended): A method for treating attention-deficit hyperactivity-disorder, a cognitive disorder, conduct disorder, oppositional defiant disorder, or depression, comprising administering to a patient in need thereof an effective amount of a compound of claim 20, or a pharmaceutically acceptable salt thereof.
- 40. (Previously presented): The method of claim 39, wherein said pharmaceutically acceptable salt is a hydrochloride salt.